Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
150 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-07-01
Study Completion Date
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In chronic pancreatitis, pancreatic fibrosis impairs the ducts patency and secretion and contributes to chronic pain. Another complication of long CP presence is pancreatic exocrine insufficiency (PEI) that is present in 30-90% of patients with CP. Currently, there are no reliable techniques for non-invasive assessment of the pancreatic fibrosis degree. The only accurate method for determining the severity of fibrotic changes in the pancreas is histological examination. Despite the high informativeness of this method, its use is limited by the necessity to obtain biopsy specimens of sufficient diagnostic volume or surgical material, which is associated with the complications risk of an invasive procedure. This makes it impossible to assess the degree of fibrosis in all the patients with pancreatic diseases.
It is possible to overcome the limitations by applying non-invasive diagnostic techniques, the development and grounding of which is planned within the framework of the Project.
It is possible to overcome the limitations by applying non-invasive diagnostic techniques, the development and grounding of which is planned within the framework of the Project.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study of Natural History of Pancreatitis
NCT00685087
Chronic Pancreatitis
COMPLETED
Fibro-inflammatory Progression From Acute to Chronic Pancreatitis
NCT03853447
Pancreatitis
Acute Pancreatitis
Recurrent Pancreatitis
+3 more
RECRUITING
AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
NCT06278272
Chronic Pancreatitis
Exocrine Pancreatic Insufficiency
Machine Learning
+1 more
COMPLETED
Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis
NCT02781987
Post-ERCP Acute Pancreatitis
COMPLETED
Fatty Liver and Pancreatic Steatosis
NCT06757348
Exocrine Pancreatic Insufficiency
Fatty Liver, Nonalcoholic
Pancreatic Steatosis
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis The degree of fibrotic changes according to the histological examination can be comparable to the degree of fibrosis of the pancreas identified by non-invasive radiology and laboratory diagnostic methods.
Aim To identify the relationship between the degree of fibrosis in the pancreas assessed by the histological examination and a complex of non-invasive radiology and laboratory diagnostic procedures.
Materials and methods Study design Prospective single-center observational study Inclusion Criteria
* age 18-99 years
* pre-planned pancreatic resection
* consent of the patient to participate in the study Exclusion Criteria
* inability to sign informed voluntary consent at the time of an inclusion to the study
* the impossibility of obtaining clinical data, data of instrumental, laboratory studies, and histological examination of the material obtained during surgical treatment.
Variables
The following parameters will be registered in the case report form (CRF) of the patient:
* demographic (sex, date of birth, age at the time of diagnosis)
* anthropometric (height, body weight, body mass index, waist circumference, hips circumference, weight loss during last 1 and 6 months)
* past medical history:
* comorbidities
* history of cholangitis
* history of bile duct drainage
* type of drainage
* type for planned surgery
* in CP:
* history of CP in years
* history of smoking and alcohol consumption
* Buchler classification for calcifying pancreatitis \[10\]
* M-ANNHEIM classification \[11\]
* reversible and irreversible complications according to M-ANNHEIM classification
* functional activity of the pancreas:
* PEI, pancreatic enzyme replacement therapy (start date, dose per day)
* type 3 diabetes mellitus (date of diagnosis, treatment received)
* bowel preparation before surgery
* characteristics of the underlying disease according to radiology examination
* thickness of the head, body, tail of the pancreas
* main pancreatic duct (MPD) width
* calcifications in the MPD and lateral branches
* assessment of the pancreas according to the Cambridge classification \[12\]
* thickness of the medial wall of the duodenum
* localization of the mass
* the largest size of the mass
* diameter of the common bile duct
* the largest size of regional lymph nodes
* involvement of arteries and veins
* ROI density without contrast, HU
* ROI density in the pancreatic phase, HU
* ROI density in the portal phase, HU
* AORTA density without contrast, HU
* AORTA density in the pancreatic phase, HU
* AORTA density in the portal phase, HU
* normalized contrast ratio of the tumor in the pancreatic phase
* normalized contrast ratio of the tumor in the portal phase
* contrast ratio, L/E
* gradient median
* laboratory:
* complete blood count (WBC, LYM, NEU, RBC, Hb, Hct, PLT)
* biochemical blood test (total protein, albumin, bilirubin, bilirubin fractions, cholesterol, iron, amylase, lipase, C-reactive protein, blood glucose, HbA1c)
* C-peptide,
* metalloproteinases (MMP) - MMP-1 and MMP-9
* hyaluronic acid,
* transforming growth factor β-1,
* fibronectin
* interleukin-10, interleukin-36
* elastase feces-1
* tumor markers: cancer embryonic antigen, CA 19-9
* bacteriological examination of bile with bacteriology analysis
* bacteriological examination of feces with bacteriology analysis
* scales
* for proximal resections:
* Fistula Risk Score \[13\]
* Updated Alternative Fistula Risk Score; ua-FRS \[14\]
* Pancreatic fistula prediction scale according to CT data \[15\]
* for distal resections:
\--- Preoperative distal fistula risk score (D-FRS) \[16\]
* intraoperative risk scale for the development of distal pancreatic fistula (D-FRS) \[16\]
* ECOG \[17\]
* ASA \[18\]
* surgery data
* surgery and intraoperative parameters:
* date of operation
* kind of operation
* operation time
* an instrument that has intersected the pancreas
* subjective assessment of pancreatic density by the surgeon
* Soft/dense
* Density from 1-5
* the width of the pancreas along the line of intersection
* MPD width along the intersection line
* number of drainages
* type of drainages
* during the formation of pancreatoenteroanastomosis:
* reconstruction type
* single or double layer anastomosis
* invagination anastomosis - yes/no
* U-shaped suture - yes / no
* implanting the pancreatic duct into the jejunum - yes / no
* for distal resection:
* stump cover - yes/no
* cover material
* postoperative complications
* pancreatic fistula
* type of pancreatic fistula according to the ISGPS classification \[19\]
* bleeding
* source of bleeding
* intra-abdominal/intraluminal
* ISGPS classification of bleeding \[19\]
* severity of complications according to the Clavien-Dindo scale \[20\]
* acute fluid collections according to the ISGPS classification
* use of octreotide postoperatively
* repeated interventions
\--- intervention type
* data of bacteriological examination of the drainages discharge
* number of days in the hospital
* readmission to hospital
* mortality
* morphological parameters
* findings accurately mapped on the surgical material acquired during macroscopic examination
* findings accurately mapped on the surgical material acquired during microscopic examination;
* the severity of fibrotic changes according to the results of a complete assessment of intra- and perilobular fibrosis;
* characteristics of fibrotic changes depending on the disease of the pancreas (cancer, pancreatitis, cystic lesions, etc.)
* degree of perilobular/intralobular fibrosis in points with its summation
* main pancreatic duct diameter
* protein plug obstruction of ducts lumen
* duct metaplasia
* inflammation
* nerve columns
Study design After signing the informed consent, past medical history data, blood, and stool tests will be collected. Multi-slice computed tomography (CT) with intravenous bolus injection of a contrast agent should be performed on an Aquilion CXL 128, 128-row CT scanner with a reconstruction algorithm with a slice thickness of 1 mm and a reconstruction step of 1 mm using non-ionic radiopaque agents with an iodine content of 370 mg/ml or 350 mg/ml. Radiopaque agents will be administered at a rate of 3.5 ml/sec, in a volume of up to 100 ml, depending on the patient's body weight. The CT examination will be carried out as standard; it is a multiphase protocol that includes non-contrast study, arterial, late arterial or pancreatic, venous, and delayed phases, with standard time distribution.
Non-invasive diagnosis of pancreatic fibrosis will be performed by assessing the contrast ratio based on sequential densitometry of the head, body and tail of the pancreas and blood in the aorta at the level of the pancreas. X-ray density measurements will be carried out in the native, late arterial, and venous phases.
X-ray density will be measured in Hounsfield units in a limited area of 0.2-0.8 cm2. The results for individual areas of the pancreas in each patient with this technique will be summarized as means and medians. The measurements will be taken by an abdominal CT radiologist with more than 5 years of experience.
In addition, a non-invasive assessment of the microvasculature based on the calculation of the median of the contrast gradient is planned to apply for patients with a need for differential diagnosis. Calculations will also be carried out based on the results of CT.
For accurate mapping of findings in the pancreas, dissection of the samples will be carried out with mandatory photo fixation. The dissection of the organ complex will be conducted according to the technique described by O.V. Paklina and G.R. Setdikova depending on the neoplastic process location. \[21\]
For the study, several sections of the pancreas will be studied:
1. Areas with macroscopically preserved architectonics/lobularity of the gland;
2. Areas with partial erasure of the pancreas pattern;
3. Areas with macroscopically visible fibrotic changes.
All samples will be taken into different cassettes with precise labeling and fixation on a macro photo. The material will be fixed in a 10% buffered formalin solution, then carried out according to the standard method. Serial 3 µm thick paraffin sections will be stained with hematoxylin and eosin.
The degree of fibrotic changes will be assessed in points separately for intra- and perilobular fibrosis. Changes in the ductal system, the presence of inflammatory elements, and their severity (scattered, nodular, etc.), changes in the vascular bed and nerve trunks will also be evaluated.
Statistical data analysis Evaluation of quantitative parameters for compliance with the normal distribution will be performed using the Shapiro-Wilk test.
For describing quantitative parameters that have a normal distribution, the obtained data are combined into variational series in which the calculation of arithmetic means (M) and standard deviations (SD), borders of the 95% confidence interval (95% CI) will be carried out.
Sets of quantitative indicators, the distribution of which differs from the normal, will be described using the values of the median (Me) and the lower and upper quartiles (Q1-Q3). Nominal parameters will be described with absolute values and percentages.
When comparing means in normally distributed populations of quantitative data, Student's t-test will be calculated. The acquired Student's t-test values will be evaluated by comparison with critical values. Differences in parameters will be considered statistically significant at a significance level of p\<0.05.
To compare independent populations in cases with no signs of a normal distribution, the Mann-Whitney U-test will be used.
Comparison of nominal data is carried out using Pearson's χ2 test, which allows assessing the significance of differences between the actual number of outcomes or qualitative characteristics of the sample falling into each category and the theoretical number that can be expected in the studied groups if the null hypothesis is true.
The Wilcoxon W-test will be used to analyze differences between two compared paired samples. In this case, the value of the parameter change will be calculated for each patient.
In order to study the relationship between phenomena represented by quantitative data, the distribution of which differed from normal, a non-parametric Spearman rank correlation coefficient method will be used.
As a quantitative measure of the effect when comparing relative indicators, the odds ratio (OR) will be used, defined as the ratio of the probability of an event occurring in a group exposed to a risk factor to the probability of an event occurring in a control group. The odds ratio is calculated based on the resulting contingency tables.
Aim To identify the relationship between the degree of fibrosis in the pancreas assessed by the histological examination and a complex of non-invasive radiology and laboratory diagnostic procedures.
Materials and methods Study design Prospective single-center observational study Inclusion Criteria
* age 18-99 years
* pre-planned pancreatic resection
* consent of the patient to participate in the study Exclusion Criteria
* inability to sign informed voluntary consent at the time of an inclusion to the study
* the impossibility of obtaining clinical data, data of instrumental, laboratory studies, and histological examination of the material obtained during surgical treatment.
Variables
The following parameters will be registered in the case report form (CRF) of the patient:
* demographic (sex, date of birth, age at the time of diagnosis)
* anthropometric (height, body weight, body mass index, waist circumference, hips circumference, weight loss during last 1 and 6 months)
* past medical history:
* comorbidities
* history of cholangitis
* history of bile duct drainage
* type of drainage
* type for planned surgery
* in CP:
* history of CP in years
* history of smoking and alcohol consumption
* Buchler classification for calcifying pancreatitis \[10\]
* M-ANNHEIM classification \[11\]
* reversible and irreversible complications according to M-ANNHEIM classification
* functional activity of the pancreas:
* PEI, pancreatic enzyme replacement therapy (start date, dose per day)
* type 3 diabetes mellitus (date of diagnosis, treatment received)
* bowel preparation before surgery
* characteristics of the underlying disease according to radiology examination
* thickness of the head, body, tail of the pancreas
* main pancreatic duct (MPD) width
* calcifications in the MPD and lateral branches
* assessment of the pancreas according to the Cambridge classification \[12\]
* thickness of the medial wall of the duodenum
* localization of the mass
* the largest size of the mass
* diameter of the common bile duct
* the largest size of regional lymph nodes
* involvement of arteries and veins
* ROI density without contrast, HU
* ROI density in the pancreatic phase, HU
* ROI density in the portal phase, HU
* AORTA density without contrast, HU
* AORTA density in the pancreatic phase, HU
* AORTA density in the portal phase, HU
* normalized contrast ratio of the tumor in the pancreatic phase
* normalized contrast ratio of the tumor in the portal phase
* contrast ratio, L/E
* gradient median
* laboratory:
* complete blood count (WBC, LYM, NEU, RBC, Hb, Hct, PLT)
* biochemical blood test (total protein, albumin, bilirubin, bilirubin fractions, cholesterol, iron, amylase, lipase, C-reactive protein, blood glucose, HbA1c)
* C-peptide,
* metalloproteinases (MMP) - MMP-1 and MMP-9
* hyaluronic acid,
* transforming growth factor β-1,
* fibronectin
* interleukin-10, interleukin-36
* elastase feces-1
* tumor markers: cancer embryonic antigen, CA 19-9
* bacteriological examination of bile with bacteriology analysis
* bacteriological examination of feces with bacteriology analysis
* scales
* for proximal resections:
* Fistula Risk Score \[13\]
* Updated Alternative Fistula Risk Score; ua-FRS \[14\]
* Pancreatic fistula prediction scale according to CT data \[15\]
* for distal resections:
\--- Preoperative distal fistula risk score (D-FRS) \[16\]
* intraoperative risk scale for the development of distal pancreatic fistula (D-FRS) \[16\]
* ECOG \[17\]
* ASA \[18\]
* surgery data
* surgery and intraoperative parameters:
* date of operation
* kind of operation
* operation time
* an instrument that has intersected the pancreas
* subjective assessment of pancreatic density by the surgeon
* Soft/dense
* Density from 1-5
* the width of the pancreas along the line of intersection
* MPD width along the intersection line
* number of drainages
* type of drainages
* during the formation of pancreatoenteroanastomosis:
* reconstruction type
* single or double layer anastomosis
* invagination anastomosis - yes/no
* U-shaped suture - yes / no
* implanting the pancreatic duct into the jejunum - yes / no
* for distal resection:
* stump cover - yes/no
* cover material
* postoperative complications
* pancreatic fistula
* type of pancreatic fistula according to the ISGPS classification \[19\]
* bleeding
* source of bleeding
* intra-abdominal/intraluminal
* ISGPS classification of bleeding \[19\]
* severity of complications according to the Clavien-Dindo scale \[20\]
* acute fluid collections according to the ISGPS classification
* use of octreotide postoperatively
* repeated interventions
\--- intervention type
* data of bacteriological examination of the drainages discharge
* number of days in the hospital
* readmission to hospital
* mortality
* morphological parameters
* findings accurately mapped on the surgical material acquired during macroscopic examination
* findings accurately mapped on the surgical material acquired during microscopic examination;
* the severity of fibrotic changes according to the results of a complete assessment of intra- and perilobular fibrosis;
* characteristics of fibrotic changes depending on the disease of the pancreas (cancer, pancreatitis, cystic lesions, etc.)
* degree of perilobular/intralobular fibrosis in points with its summation
* main pancreatic duct diameter
* protein plug obstruction of ducts lumen
* duct metaplasia
* inflammation
* nerve columns
Study design After signing the informed consent, past medical history data, blood, and stool tests will be collected. Multi-slice computed tomography (CT) with intravenous bolus injection of a contrast agent should be performed on an Aquilion CXL 128, 128-row CT scanner with a reconstruction algorithm with a slice thickness of 1 mm and a reconstruction step of 1 mm using non-ionic radiopaque agents with an iodine content of 370 mg/ml or 350 mg/ml. Radiopaque agents will be administered at a rate of 3.5 ml/sec, in a volume of up to 100 ml, depending on the patient's body weight. The CT examination will be carried out as standard; it is a multiphase protocol that includes non-contrast study, arterial, late arterial or pancreatic, venous, and delayed phases, with standard time distribution.
Non-invasive diagnosis of pancreatic fibrosis will be performed by assessing the contrast ratio based on sequential densitometry of the head, body and tail of the pancreas and blood in the aorta at the level of the pancreas. X-ray density measurements will be carried out in the native, late arterial, and venous phases.
X-ray density will be measured in Hounsfield units in a limited area of 0.2-0.8 cm2. The results for individual areas of the pancreas in each patient with this technique will be summarized as means and medians. The measurements will be taken by an abdominal CT radiologist with more than 5 years of experience.
In addition, a non-invasive assessment of the microvasculature based on the calculation of the median of the contrast gradient is planned to apply for patients with a need for differential diagnosis. Calculations will also be carried out based on the results of CT.
For accurate mapping of findings in the pancreas, dissection of the samples will be carried out with mandatory photo fixation. The dissection of the organ complex will be conducted according to the technique described by O.V. Paklina and G.R. Setdikova depending on the neoplastic process location. \[21\]
For the study, several sections of the pancreas will be studied:
1. Areas with macroscopically preserved architectonics/lobularity of the gland;
2. Areas with partial erasure of the pancreas pattern;
3. Areas with macroscopically visible fibrotic changes.
All samples will be taken into different cassettes with precise labeling and fixation on a macro photo. The material will be fixed in a 10% buffered formalin solution, then carried out according to the standard method. Serial 3 µm thick paraffin sections will be stained with hematoxylin and eosin.
The degree of fibrotic changes will be assessed in points separately for intra- and perilobular fibrosis. Changes in the ductal system, the presence of inflammatory elements, and their severity (scattered, nodular, etc.), changes in the vascular bed and nerve trunks will also be evaluated.
Statistical data analysis Evaluation of quantitative parameters for compliance with the normal distribution will be performed using the Shapiro-Wilk test.
For describing quantitative parameters that have a normal distribution, the obtained data are combined into variational series in which the calculation of arithmetic means (M) and standard deviations (SD), borders of the 95% confidence interval (95% CI) will be carried out.
Sets of quantitative indicators, the distribution of which differs from the normal, will be described using the values of the median (Me) and the lower and upper quartiles (Q1-Q3). Nominal parameters will be described with absolute values and percentages.
When comparing means in normally distributed populations of quantitative data, Student's t-test will be calculated. The acquired Student's t-test values will be evaluated by comparison with critical values. Differences in parameters will be considered statistically significant at a significance level of p\<0.05.
To compare independent populations in cases with no signs of a normal distribution, the Mann-Whitney U-test will be used.
Comparison of nominal data is carried out using Pearson's χ2 test, which allows assessing the significance of differences between the actual number of outcomes or qualitative characteristics of the sample falling into each category and the theoretical number that can be expected in the studied groups if the null hypothesis is true.
The Wilcoxon W-test will be used to analyze differences between two compared paired samples. In this case, the value of the parameter change will be calculated for each patient.
In order to study the relationship between phenomena represented by quantitative data, the distribution of which differed from normal, a non-parametric Spearman rank correlation coefficient method will be used.
As a quantitative measure of the effect when comparing relative indicators, the odds ratio (OR) will be used, defined as the ratio of the probability of an event occurring in a group exposed to a risk factor to the probability of an event occurring in a control group. The odds ratio is calculated based on the resulting contingency tables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pancreatic Fibrosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-99 years
* pre-planned pancreatic resection
* consent of the patient to participate in the study
* pre-planned pancreatic resection
* consent of the patient to participate in the study
Exclusion Criteria
* inability to sign informed voluntary consent at the time of an inclusion to the study
* the impossibility of obtaining clinical data, data of instrumental, laboratory studies, and histological examination of the material obtained during surgical treatment.
* the impossibility of obtaining clinical data, data of instrumental, laboratory studies, and histological examination of the material obtained during surgical treatment.
Minimum Eligible Age
18 Years
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Moscow Clinical Scientific Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dmitry S. Bordin, MD PhD
Role: PRINCIPAL_INVESTIGATOR
A.S. Loginov Moscow Clinical Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A.S. Loginov Moscow Clinical Scientific Center
Moscow, , Russia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Russia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.
Reference Type
BACKGROUND
Melton E, Qiu H. Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis. Int J Mol Sci. 2020 Sep 4;21(18):6458. doi: 10.3390/ijms21186458.
Reference Type
RESULT
Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019 Jan 21;18(1):14. doi: 10.1186/s12943-018-0927-5.
Reference Type
RESULT
Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, Gatenby PAC, Jones SA, de Lusignan S. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care. 2017 Nov;40(11):1486-1493. doi: 10.2337/dc17-0542. Epub 2017 Aug 31.
Reference Type
RESULT
Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019 Mar 21;12:129-139. doi: 10.2147/CEG.S168266. eCollection 2019.
Reference Type
RESULT
Uc A, Andersen DK, Bellin MD, Bruce JI, Drewes AM, Engelhardt JF, Forsmark CE, Lerch MM, Lowe ME, Neuschwander-Tetri BA, O'Keefe SJ, Palermo TM, Pasricha P, Saluja AK, Singh VK, Szigethy EM, Whitcomb DC, Yadav D, Conwell DL. Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas. 2016 Nov;45(10):1365-1375. doi: 10.1097/MPA.0000000000000713.
Reference Type
RESULT
Shimosegawa T. A New Insight into Chronic Pancreatitis. Tohoku J Exp Med. 2019 Aug;248(4):225-238. doi: 10.1620/tjem.248.225.
Reference Type
RESULT
Ge QC, Dietrich CF, Bhutani MS, Zhang BZ, Zhang Y, Wang YD, Zhang JJ, Wu YF, Sun SY, Guo JT. Comprehensive review of diagnostic modalities for early chronic pancreatitis. World J Gastroenterol. 2021 Jul 21;27(27):4342-4357. doi: 10.3748/wjg.v27.i27.4342.
Reference Type
RESULT
Buchler MW, Martignoni ME, Friess H, Malfertheiner P. A proposal for a new clinical classification of chronic pancreatitis. BMC Gastroenterol. 2009 Dec 14;9:93. doi: 10.1186/1471-230X-9-93.
Reference Type
RESULT
Schneider A, Lohr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol. 2007 Feb;42(2):101-19. doi: 10.1007/s00535-006-1945-4. Epub 2007 Mar 12.
Reference Type
RESULT
Sarner M, Cotton PB. Classification of pancreatitis. Gut. 1984 Jul;25(7):756-9. doi: 10.1136/gut.25.7.756.
Reference Type
RESULT
Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013 Jan;216(1):1-14. doi: 10.1016/j.jamcollsurg.2012.09.002. Epub 2012 Nov 2.
Reference Type
RESULT
Mungroop TH, Klompmaker S, Wellner UF, Steyerberg EW, Coratti A, D'Hondt M, de Pastena M, Dokmak S, Khatkov I, Saint-Marc O, Wittel U, Abu Hilal M, Fuks D, Poves I, Keck T, Boggi U, Besselink MG; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Updated Alternative Fistula Risk Score (ua-FRS) to Include Minimally Invasive Pancreatoduodenectomy: Pan-European Validation. Ann Surg. 2021 Feb 1;273(2):334-340. doi: 10.1097/SLA.0000000000003234.
Reference Type
RESULT
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
Reference Type
RESULT
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CM, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. doi: 10.1016/j.surg.2016.11.014. Epub 2016 Dec 28.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
https://www.evidencio.com/models/show/2587
Matteo de Pastena, Eduard A van Bodegraven, Marc G Besselink, Claudio Bassi
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Use of Perfusion CT Derived Parameters as Early Acute Pancreatitis Severity Biomarker Compared to Clinico Biological Score
NCT03456557
COMPLETED
NA
Fatigue, Psychological Comorbidity and Quality of Life Among Patients With Chronic Pancreatitis in China.
NCT05489003
UNKNOWN
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis
NCT06899087
RECRUITING
Translation and Validation of Chinese COMPAT-SF
NCT06917716
RECRUITING
Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT
NCT06510036
RECRUITING
Natural Course and Therapeutic Effect of Chronic Pancreatitis
NCT06925204
RECRUITING
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
NCT03850977
COMPLETED
Diagnosis of Fatty Pancreas by FibroScan
NCT07255989
COMPLETED
NA
Classification and Comparison of Early-onset and Late-onset Idiopathic Chronic Pancreatitis
NCT03953937
UNKNOWN
Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis
NCT03566173
COMPLETED
An Observational Study on the Natural Course of Chronic Pancreatitis
NCT04574297
ACTIVE_NOT_RECRUITING
Establishment of Clinical Staging of Chronic Pancreatitis Based on Histopathology of Pancreatic Duct Biopsy
NCT05352932
UNKNOWN
Significance of Collections Around Colon in Patients With Acute Necrotizing Pancreatitis
NCT03411629
COMPLETED
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
NCT02682394
UNKNOWN
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
NCT05410795
UNKNOWN
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
NCT05804409
UNKNOWN
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
NCT01600105
COMPLETED
PHASE4
Pancreas Volume and Diabetes Status Following Pancreatectomy
NCT02823678
UNKNOWN
Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma
NCT06867172
RECRUITING
Methods to Detect Liver Fibrosis
NCT03027700
TERMINATED
NA
Identification of the Impact of Acute Pancreatitis on Quality of Life
NCT04222075
UNKNOWN
The Diagnosis of Chronic Pancreatitis
NCT01059669
UNKNOWN
Online Health Assessment to Support Comprehensive Care
NCT02122302
WITHDRAWN
NA
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
NCT03961516
COMPLETED
Relationship of CP and AP
NCT04670705
COMPLETED